Mandate

Vinge advises Santander Consumer Finance in connection with the divestment of its Swedish and Norwegian Credit Card and Sales Financing business

Vinge has advised Santander Consumer Bank AS in connection with the sale of its Swedish and Norwegian credit card business as well as the sales financing business that Santander currently operates in partnership with Elkjøp in Norway and Elgiganten in Sweden to Avida Finans AB (publ).

The business includes approximately 450 000 private customers with a total outstanding performing loan volume of approximately 4 billion SEK. The transaction is expected to close on 31 December 2024 and is still subject to applicable regulatory approvals.

Vinge's consisted of Christina Kokko, Matthias Pannier, Manon de Cooman, Isabelle Wållgren, Erik Kochbati (M&A), Eva Fredrikson, Jolene Reimerson, Mathilda Persson, Elis Allmark, Nicklas Thorgerzon (Commercial Agreements, IT and GDPR), Viveka Classon, Caroline Krassén, Sara Hedgren (Financial Services), Malin Malm Waerme (IP), Albert Wållgren (Banking and Finance), Victor Ericsson (Tax), Sam Seddigh, Emil Lindwall, Jonatan Stentorp (Employment) samt Carl Bruneheim och Cecilia Loctander (Transaction Support).

Read Avida’s press release here.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026